5. "Full Market Awareness" A professional relations company and consulting firm Contact: Sean McDonald smcdonald@acornmanagementpartners.com 941.208.3919 Atlanta,Georgia & Sarasota,Florida Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISEMENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed before making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers make no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harbor Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in any and/or all profile/ research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various fa ctors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predictions, expectat ions, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stat ements in this action may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by compan ies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its web s ite.

4. Continue Reading for Management Background & Our Disclaimer Recent News: • Life Sciences Investor Forum: Company Executives Present Live June 23rd • Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update • Emmaus Life Sciences to Present at Investor Conferences in May • Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution • Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Hematology • Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update • Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List • Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari® • Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Hematology • Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference Management Team: Yutaka Niihara M.D., M.P.H. – Chairman & CEO Distinguished Clinician and Principal Inventor of Endari® • Physician specialist for Los Angeles County from 1992 to 2009, licensed to practice medicine in both the U.S. and Japan • Published author in the area of sickle cell disease • Principal inventor of Endari® • Professor of Medicine at the David Geffen School of Medicine at UCLA Willis Lee, MS Vice Chairman & Chief Operating Officer George Sekulich Senior Vice President of Global Commercialization & Chief Information Officer Charles Stark, Pharm.D. Senior Vice President of Medical Affairs, Research, & Regulatory Yasushi Nagasaki, CPA Chief Financial Officer Dale E. Short, JD General Counsel & Corporate Secretary Collective Experience:

3. Continue Reading for Recent News, Management Background & Our Disclaimer • Commercial stage company marketing Endari® o a safe and efficacious therapy for sickle cell disease • Targeting large addressable markets in underserved patient populations • Experiencing year-over-year revenue growth • Clinical pipeline with multiple shots on goal • Experienced leadership team to execute corporate strategy • Securing captive source of API for Endari® and product candidates 2019 Highlights • $22.8M Net Revenue • Launch of Commercial Co-Payment Assistance Program • Transition from an external contract sales force to an internal sales team 2020 Highlights • $23.2M Net Revenue • APCER Life Sciences confirmed the safety profile and reported no serious safety concerns • FDA revised the safety label to add “clinical benefit was observed irrespective of hydroxyurea" • Approved by Israeli Ministry of Health • Dubai regional office opened L- Glutamine: Research in new applications • Diverticulosis: o Type 2 Diabetes: Phase 1 — trial using Endari® • Sickle Cell Disease: o Burn Injuries: Phase 3 — study product provided by Emmaus o Pancreatic Cancer: Phase 1 — study product provided by Emmaus Continuous development and expansion: While the initial focus and success was on rare and orphan diseases with unmet needs, Emmaus is now extending it's efforts to include conditions and diseases affecting larger populations, also with un met needs, including Diverticulosis. In the U.S., this affects an estimated 40% of 60-year-olds and 70% of 80-year-olds. Of whom, 10% - 20% will develop into diverticulitis, resulting in abdominal pain, nausea, vomiting, constipation, diarrhea, fever, and leukocytosis Investment Highlights: Investor Presentation: Discovering, developing, and commercializing innovative therapies to improve the quality of life for under-served patients and their communities. - Emmaus

2. Continue Reading for More Information, Recent News, Management Background and Our Disclaimer... Global Strategy: Endari® has received commercial approval with United States FDA, Israeli Ministry of Health and the United Arab Emirates. The company has submitted and pending approval in the Kingdom of Saudi Arabia, Kuwait, Bahrain. The company is in the process of gaining approval from the Gulf Cooperation Council (GCC) Countries and in an Early Access program in the U.K., France, and Turkey Europe ▪ Focus on early access programs ▪ EMA and UK approval process Middle East & North Africa (MENA) ▪ Distribution partners in place ▪ Opened Dubai office in 2020 Latin America ▪ With a focus on Brazil and Colombia $3.4 Billion R est of W orld $480 Million U.S. and EU U.S. Expansion: Target: • Hematologists • Physicians • Treatment centers Support: • Involvement with local and national SCD foundations • Excellent payer coverage • Managed Medicaid (primary payer) • Children’s Health Insurance Plan (low-income support) • Commercial Insurance • Medicare • Patient assistance programs Expansion: • Network of over 600 pharmacies and growing • Big 3 distributors: AmerisourceBergen, Cardinal and McKesson • RXs filled in 44 states, Puerto Rico and Washington, D.C. • Contracted with pharmacy benefit managers • Additional sales opportunities: group purchasing organizations, specialty pharmacies Growth Opportunities: Telehealth: • 100,000 sickle cell patients in the US o 25,000 patients can be accessed through physicians o 75,000 do not and can be accessed directly through Telehealth Advantages of Telehealth: • Endari does not require bloodwork in order to be prescribed. • Endari can be delivered directly to patients’ homes • Same-day physician authorization and prescription • Endari gets shipped within 3 business days.

1. AMP Quick Facts Emmaus Life Sciences, Inc. ( OTCQX : EMMA ) Acorn Management Partners, LLC August 202 2 OTCQX: EMMA Price: $ . 39 Date: 0 8 / 1 0 /2 2 Fiscal Year: 12/31 MKT Cap: ~ 17 . 30 m Inside Ownership: ~ 30 % S/O*: ~ 49.3 m Held @ DTC : ~ 37.0 m AVG Vol.: ~ 1 2 . 90 k For More Information Please Email: Victor Rios vrios@acornmanagement partners.com Industry : Life Sciences "Biopharmaceutical" * As of most recent filing Continue Reading for More Information, Recent News, Management Background & Our Disclaimer... Emmaus Life Sciences, Inc. (EMMA) is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Emmaus's lead commercial product is Endari® , an oral powder, pharmaceutical grade, L-glutamine treatment, indi cated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Sickle Cell Di sease Sickle cell disease (SCD) is an autosomal recessive disorder, meaning you inherit two changed genes (mutations), one from each parent. These disorders are usually passed on by two carriers. Their health is rarely affected, they have one changed gene (recessive gene) and one unaffected gene (dominant gene) for the condition. About 1 in 12 African-American people are carriers of this disease. One in 500 African-American babies is born with it. Sickle cell causes your red blood cells to be stiff and sticky so they can’t easily move oxygen through your body. This puts you at risk for painful complications and severe infections. Endari® (by Emmaus) Endari® is an effective solution for many patients affected by Sickle Cell Disorder and the only safe treatment option for some. Broad indication Patient age range Black box warning Lab tests required EndariÆ (L -glutamine) Hydroxyurea Oxbryta (Global Blood Therapeutics) Adakveo 5+ years old 18+ years old, used off label for pediatrics Siklos (Hydroxyurea) (Amedica) 2+ years old 4+ years old 16+ years old YES NONE NONE NO YES YES NO YES YES NO NONE YES NO NONE YES SCD affects an estimated 20M - 25M patients worldwide, predominately in Africa, the Middle East, India, South America, and Mediterranean regions. ( see next page for Global Strategy ) '21 Revenue: $ 20.61 m